RecruitingPhase 2NCT04374305
17
studies recruiting now
as of 7 Sept 2026
103
studies registered in total
as of 7 Sept 2026
3
countries with a recruiting site
as of 7 Sept 2026
25 Mar 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNCT00598351
Natural History Study of Patients With Neurofibromatosis Type 2
RecruitingNot applicableNCT04859335
Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma
RecruitingEarly phase 1NCT07493447
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
RecruitingNot applicableNCT07479446
Oliceridine Versus Sufentanil for Postoperative Nausea in Cerebellopontine Angle Surgery
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 17 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Vestibular schwannoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Vestibular schwannoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations.
Treatments being studied
6 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Losartan
Phase 2Nilotinib
Phase 2Fluorescein Sodium (Fluor-amps)
Phase 2Bevacizumab (Abevmy)
Phase 2Nimodipine (Nimodipine)
Phase 1Triamcinolone Acetonide (Adcortyl)
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).